NCT01709331View on ClinicalTrials.gov

A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 11, 2013

Primary Completion Date

April 8, 2015

Study Completion Date

April 8, 2015

Conditions

HypogonadismHypogonadotropic Hypogonadism

Interventions

DRUG

Corifollitropin alfa

Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks

DRUG

hCG

hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)

All Listed Sponsors

lead

Organon and Co

INDUSTRY